How does ATHA's Q4 2024 EPS forecast compare to past trends?
4/3/2025 05:37pm
Athira Therapeutics' (ATHA) Q4 2024 EPS forecast of -$2.52 is an improvement compared to the EPS of -$2.53 recorded in Q4 2022 and -$3.09 in Q4 2023. This indicates a trend towards improved financial performance for the company, although it is important to note that a negative EPS suggests that the company is currently unprofitable.
|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|ATHA|ATHA.O|Athira|2022 Q1|-124.00000000000003|-0.56|185|
|ATHA|ATHA.O|Athira|2022 Q2|-71.05263157894737|-0.65|185|
|ATHA|ATHA.O|Athira|2022 Q3|-26.190476190476204|-0.53|185|
|ATHA|ATHA.O|Athira|2023 Q1|-30.357142857142843|-0.73|185|
|ATHA|ATHA.O|Athira|2023 Q2|-20|-0.78|185|
|ATHA|ATHA.O|Athira|2023 Q3|-64.1509433962264|-0.87|185|
|ATHA|ATHA.O|Athira|2024 Q1|5.479452054794526|-0.69|185|
|ATHA|ATHA.O|Athira|2024 Q2|10.256410256410266|-0.7|185|
|ATHA|ATHA.O|Athira|2024 Q3|13.793103448275861|-0.75|185|